{
    "elements": [
        {
            "type": "table",
            "sequence_num": 1,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT RESEARCH APPLICATIONS"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP055"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "th12 December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th11 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins, R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Lead Clinical Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 2,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Christine Catley"
                    },
                    {
                        "text": "Senior renal research nurse"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Stacey Cotterell"
                    },
                    {
                        "text": "Clinical research coordinator"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP003 SAEs (Sponsored) MEHTSOP005 Informed Consent MEHTSOP062 Trial Master File (Sponsored) MEHTSOP061 Research Staff Training SOP-07- Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP059 Amendments MEHTSOP043 Serious Breaches (Sponsored) MEHTSOP057 Sponsor Oversight MEHTSOP055 Research Applications MEHTSOP051 DSURs (Sponsored) MEHTSOP050 Archiving of Essential Documents MEHTSOP046 Study Closure MEHTSOP044 Management of Source Data"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "12th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 6,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Applicable"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 - Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff who are involved in the initiation and set-up of research studies sponsored by MEHT which involve Investigational Medicinal Products (IMPs) or non-CE marked devices which require regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA). This document also sets out how to go about obtaining Ethical and Health Research Authority (HRA) approval for all research studies that are sponsored by MEHT."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this SOP is to describe the responsibilities and procedures for applying for and maintaining a Clinical Trials Authorisation (CTA) and procedures for applying for Research Ethics Committee (REC)/HRA approval for Clinical Trials of an Investigational Medicinal Product (CTIMPs) sponsored by MEHT to ensure compliance with the applicable regulations. This responsibility is delegated to the Chief Investigator (CI) or delegated individual (DI) for MEHT sponsored CTIMPs. This SOP is intended to provide a detailed guidance to ensure that the Sponsor maintains the quality of every aspect of the clinical trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 2.2,
                "text": "A CTA is required only in trials of medicinal products. These are substances, or combinations of substances, which either prevent or treat disease in human beings or are administered to human beings with a view to making a medical diagnosis, or to restore, correct or modify physiological functions in humans."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 2.3,
                "text": "Any research that fulfils the definition of a clinical trial will require a CTA from the MHRA. A CTA will only be issued if there are no objections to the research proposal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 2.4,
                "text": "Clinical studies involving only medical devices, food supplements or other non- medicinal therapies (such as surgical interventions) may require other regulatory approvals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 2.5,
                "text": "All MEHT sponsored CTIMPs will not receive R&D confirmation to commence unless a valid CTA approval is received by the trial investigator."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 2.6,
                "text": "HRA/REC reviews all research projects that involve NHS patients or access to data, organs or other bodily material of past or present patients."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 2.7,
                "text": "All MEHT sponsored CTIMPs will not receive R&D confirmation to commence unless REC approval is received by the trial investigator."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employee (including those with an honorary research contract or letter of access) involved with CTIMPs sponsored by MEHT including, but not limited to, Unit Heads, Chief Investigators (CI), Principal Investigators (PI), Consultants, Co- investigators, Research Fellows, Clinical Trial Pharmacists, Research Managers, Statisticians, Research nurses, Research Midwives, Allied Health Professionals, Trial Coordinators & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "The Sponsor"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "The Sponsor should risk assess the clinical trial and ensure that, if appropriate, they provide approval to the study CI to apply for regulatory and REC approval. MHRA and REC approval should be sought once funding has been secured, sponsorship agreed in principle and the trial protocol (related trial documents) have been finalised."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "The Chief Investigator"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "text": "The CI/Delegated Individual (DI) is responsible for ensuring that the regulatory and HRA/REC applications are completed and approval obtained as delegated by the study Sponsor. The CI/DI must ensure that the draft CTA is reviewed by the Clinical Trial Pharmacist before the application is submitted and ensure that pharmacy review subsequent amendments relating to the management of the IMP(s) before they are submitted."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "The Research and Development Department"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 0,
                "text": "The R&D Office is responsible for ensuring that the applicable research governance checks are completed prior to the provision of the R&D confirmation letter. They are also responsible for ensuring that any subsequent amendments receive review by the applicable staff and regulatory and/or HRA/REC approval prior to implementation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "Pharmacy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "text": "The Clinical Trial Pharmacist is responsible for reviewing and providing oversight for CTA applications and subsequent substantial amendments which impact the management of the trial IMP(s) thereafter."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Classification of Clinical Trials of an Investigational Medicinal Product (CTIMPs)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "To find out whether a clinical trial is covered by the Clinical Trials Directive 2001/20/EC, an algorithm \u2018Is it a clinical trial of a medicinal product' available from"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "text": "the MHRA website can be used: https://www.gov.uk/guidance/clinical-trials-for-medicines-apply-for-authorisation-in- the-uk#when-a-clinical-trial-authorisation-cta-is-needed"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "text": "5.1.1 If, after working through the algorithm, there is still uncertainty, the R&D Department will advise and assist investigators in contacting the MHRA Clinical Trial Helpline. A copy of the protocol or protocol proposal should be emailed to the MHRA alongside the request."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 1,
                "text": "5.1.2 Clinical trials involving only medical devices, non-interventional trials and clinical trials involving food supplements"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Clinical trials involving only medical devices or non-medicinal therapies (such as surgical interventions) are not covered by clinical trial regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "\u25cf In addition the regulations do not apply to non-interventional trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Clinical trials with food supplements are also not covered by clinical trials regulations; however, where a food supplement is presented as a pharmaceutical form, and is being evaluated for a medicinal purpose, then it will be considered a medicine and the requirements of the regulations will apply"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 1,
                "text": "5.1.3 Clinical trials involving medical devices and medicines"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Clinical trials involving a medicine and a medical device will be subject to clinical trials regulations and may also be subject to medical device regulations depending on the purpose of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "text": "\u25cf In such cases, the R&D Department will advise and assist investigators in contacting the MHRA to check the regulatory position"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Advice from the MHRA Devices Division should be sought for clinical trials involving  non-CE  marked  devices  or  CE  marked  devices  used  outside  the conditions of the CE marking"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 1,
                "text": "5.1.4 Clinical trials of non-investigational medicinal products (nIMPs)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Some clinical trials also involve medicinal products which are classified as non- investigational medicinal products (nIMPs). Standard of care medicines that are already being administered to a subject, but are continued during the clinical trial are generally considered to be nIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "\u25cf If further clarification is required as to whether a product is an IMP or nIMP, further information is available from the MHRA website"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Clinical Trial Authorisation Application"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "text": "5.2.2 Once a clinical trial has been classified as a CTIMP, the CTA submission package will be prepared and submitted by the CI/DI for MEHT sponsored CTIMPs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Registering with EudraCT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "5.3.1  In order for a clinical trial to be considered for authorisation, it must be registered on the European Clinical Trials Database \u2013 EudraCT. This is done by obtaining a unique reference number for each clinical trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Obtaining a EudraCT Number"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "text": "5.4.1  This is done by following an automated process that is accessed via the EudraCT website."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Follow EudraCT Number Step 1   Apply for a EudraCT Number  An email containing the security code, which is valid for 24hrs, will be sent to the email address entered in Step 1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Once the security code has been received, follow the EudraCT Number Step 2 instructions ensuring that all fields are completed"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "\u25cf An automated email detailing the unique EudraCT number for the trial will be sent to the email address entered in Step 1. This email will be printed and filed in the TMF, a copy of this is required as part of the CTA submission package. This number must be quoted on all future correspondence with the MHRA and REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "The CTA application and submission"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 1,
                "text": "5.5.1 Detailed information on what to submit and how to submit the application is available on the  MHRA website. The application may be completed via the Integrated Research Application System (IRAS) system."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 The CI/DI must send the draft version of the IRAS form to the Clinical Trial Pharmacist to allow the Pharmacist to review the IMP section of the form. The Pharmacist should review and authorise/provide guidance on the following aspects of the CTA submission to the MHRA;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Review the application for each IMP identified in the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Sample label(s) to be used for the trial IMP(s) - The Pharmacist must approve any labels submitted or design the label to be used. Notification of this approval should be documented and provided to the CI/DI and R&D Department."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "5.5.3 Although the CI will sign the application form as the \u201cApplicant\u201d the R&D Director or R&D Manager will be the \u201ccontact\u201d for the CI and Sponsor. This is to ensure that all correspondence from the MHRA is sent to the Sponsor."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 1,
                "text": "5.5.4 Prior to submission to the MHRA the CI/DI should liaise with the R&D Director or R&D Manager to authorise and arrange the payment (by bacs transfer) of the required fee to the MHRA as detailed on the MHRA website. The EudraCT number must be included with the payment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "text": "5.5.5 Proof of payment of the fee must be sent with the submission package to the MHRA to ensure the validity of the application."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "text": "5.5.6 An electronic signature of the submitted application form and supporting documents will be filed in the Trial Master File (TMF) and R&D file. A copy of the signed CTA and applicable approvals should be maintained in the trial specific pharmacy file."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "5.5.7 Upon receipt of the MHRA approval letter, the CI/DI should communicate any IMP related outstanding actions requested by the MHRA as part the approval to the Pharmacist, who will work with the CI/DI to ensure these actions are completed. The R&D Department must be informed when these actions are completed and documented."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 1,
                "text": "What are the possible outcomes?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "text": "5.5.8 There are two possible outcomes:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Acceptance (with or without conditions)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Grounds for non-acceptance."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "5.5.9 Some acceptance letters state conditions or remarks. The remarks must be responded to prior to the start of the study. If there are grounds for non-acceptance,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "the CI/DI should reply within  days (30 days for gene therapy, somatic cell therapy or products containing genetically modified organisms) to submit an amended request for authorisation. These periods may be extended in certain circumstances."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "text": "5.5.10 The amended request is assessed within a total of 60 days from receipt of the initial application (90 days for gene therapy products) and there are two possible outcomes:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Acceptance (with or without conditions)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Grounds for non-acceptance."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 1,
                "text": "Terms and conditions of approval"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "5.5.11 For a multicentre trial, the MHRA must be notified of each additional investigator using the Annex 2: Notification of an Amendment form (See section 6.0). Ethics approval for each additional investigator should also be obtained."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "5.5.12 In accordance with regulation 27, you must notify the MHRA within 90 days of the conclusion of the trial."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "5.5.13 The MHRA may suspend or terminate a clinical trial where it feels the conditions for authorisation are not being met."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "MHRA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 1,
                "text": "Type A Clinical Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "5.6.1 All interventional trials of an IMP conducted in the UK require an approved CTA from the MHRA before they may commence. However, the majority of Type A trials conducted in the UK will only require to be notified to the MHRA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "5.6.2 This will involve the sending of the standard EudraCT application form as detailed in section  and accompanying documents in the usual way. A letter of acknowledgement will be sent to the CI/DI by the MHRA with an accompanying note to say that the trial may go ahead after 14 days from receipt of notification, if the MHRA has not raised any objections."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "5.6.3 Therefore the acknowledgement letter will act as the authorisation. Further details are provided on the MHRA website."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "5.6.4 (NB - Ethics Committee role: All interventional trials of an IMP conducted in the UK will continue to require a positive opinion from a Research Ethics Committee before they may commence)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 1,
                "text": "Types B & C Clinical Trials"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "5.6.5 The CTA will be validated on receipt at the MHRA and an acknowledgement letter will be sent to the Sponsor contact. If the application is valid then the assessment period will begin. This starts from the date of receipt of a valid application."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "5.6.7 If the application is not valid the MHRA will inform the CI/DI contact."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "5.6.8 The full submission package may need to be re-submitted, however the MHRA should advise on the requirements for resubmission. The CI/DI should contact the Sponsor contact for further advice in such circumstances if required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "5.6.9 Each application will be assessed by the MHRA within 30 days from the date of validation of the application. They will provide an initial response to all valid applications within 30 days of receipt."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "text": "5.6.10 If the Notice of Acceptance letter from the MHRA places any conditions on the CTA these must be responded to and a confirmation of satisfactory resolution received from the MHRA for the approval to be valid. The R&D Department should verify that the CTA authorisation letter including any such remarks is responded to prior to Sponsor activation of the trial/Sponsor approval of amendment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "text": "5.6.11 All correspondence relating to the CTA will be filed within the TMF with copies of relevant applications and approvals in the R&D File."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "text": "5.6.12 It is a requirement of the CTA that a favourable opinion of a REC is sought and maintained."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "5.6.13 The CI/DI is responsible for the submission of the initial application to the REC to obtain favourable opinion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "5.6.14 Prior to the activation of the study/approval of substantial amendments the R&D Department will verify the governance requirements as part of the initiation visit (see gSOP-18)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "5.6.15 The EudraCT number, CTA number, protocol code and product name must be quoted in all CTA submissions, amendments, Development Update Safety Reports and End Of Trial notifications."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 1,
                "text": "End Trial Report"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "5.6.16 Within 12 months from the End of Trial Declaration the Final Trial Report is required to be submitted to the MHRA. Prior to submission to the MHRA, the CI/DI will submit the report to the RDAG for final review and Sponsor approval. This final report will be sent to the MHRA within one year of the end of the trial and a copy filed within the TMF and R&D File (see gSOP-21)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 1,
                "text": "Other activities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "5.6.17 The following also contribute to the maintenance of the CTA but are outside the scope of this SOP:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Adverse Events (see gSOP-02)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Development Safety Update Reports (see gSOP-15)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "text": "How and where to apply for CTA?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "5.6.18 Applicants should submit documents electronically, with one PDF file for each document. The MHRA will not accept paper documents."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 1,
                "text": "5.6.19 Information on the standards and conventions for submitting electronic documents, including the acceptable file name, can be found at the  MHRA WebPages for submitting a CTA."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "text": "MHRA Fees"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "text": "5.6.20 The MHRA charge an initial submission fee and an annual service fee for all open CTA's. Details of current fees may be found on the MHRA website"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "prefix": 5.7,
                "text": "Application to the HRA/REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 1,
                "text": "5.7.1 HRA/REC Application Process"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "CI/DI to set up an IRAS account if one is not already held"
            }
        },
        {
            "type": "image",
            "sequence_num": 117,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.002.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "CI/DI complete IRAS application form ready for submission to REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "For MEHT sponsored studies, a draft copy of the completed IRAS form must be submitted to the R&D office for review and approval before submission to REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "text": "Once approval from R&D has been granted, CI/DI to sign application form"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "Sponsor's representative to sign the completed application form. For MEHT sponsored studies, this will be the R&D Co-Director or R&D Manager"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "text": "CI/DI to collate submission package to REC using the REC application check list."
            }
        },
        {
            "type": "image",
            "sequence_num": 123,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 0,
                "text": "Once application complete, CI/DI to book the study for review"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "text": "Application plus all supporting documentation should be sent to the REC office by the agreed submission date"
            }
        },
        {
            "type": "image",
            "sequence_num": 126,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "text": "The REC Application and Submission"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "text": "5.7.2 All the data required to complete the application to for authorisation of a clinical trial can be completed within IRAS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "text": "5.7.3 The IRAS form should be completed by the CI/DI"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 0,
                "text": "5.7.4 Sections covering the Ionising Radiation (Medical Exposures) Regulations 2000 (IRMER) must be completed by and signed by the lead Medical Physics Expert (MPE) and lead Clinical Radiation Expert (CRE)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "5.7.5 The application must be signed by the CI/DI and approved by the R&D Department before submission. An electronic signature should be completed for all MEHT sponsored CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "text": "5.7.6 The application should also be signed by the Sponsor's representative"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "text": "5.7.7 Submissions should be completed according to the REC application checklist"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "5.7.8 Once the application is complete and ready for submission, the application should be booked for review"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "text": "What are the possible outcomes?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "5.7.9 Once the application is received by REC they will check that it is valid and send a validation letter confirming this."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "text": "5.7.10 If the application submitted is valid, the application will be assessed and discussed at the REC meeting and the applicant will be sent a letter informing them of:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Favourable opinion"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Provisional opinion"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Rejection"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 0,
                "text": "5.7.11 If the letter states a provisional opinion, the CI/DI will need to address all the conditions and remarks and submit their response back to the REC for their final opinion. The CI/DI must provide a copy of this documentation to the R&D Department and maintain a copy in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "text": "5.7.12 The RECs are required to give an opinion within 60 days of receipt of a valid application. However the \u2018clock stops' if further information is requested and restarts when this information is received by the REC."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "5.7.13 The CI/DI will ensure all documentation submitted to the REC and all correspondence received from the REC is sent to the R&D Department and a copy maintained in the TMF."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 1,
                "text": "Conditions of approval"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "text": "5.7.14 Favourable ethical opinion letters will also list conditions of that favourable opinion including:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "\u25cf R&D confirmation being obtained, where NHS sites are involved"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Obtaining a CTA for CTIMPs"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Other specified conditions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "5.7.15 These must be reviewed, actions taken, responses made (where necessary) and all related documentation retained in the TMF and R&D file to prove these conditions have been met."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 1,
                "prefix": 5.8,
                "text": "Substantial Amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "5.8.1 The CI/DI should prepare, submit and manage the maintenance of the CTA on behalf of the Sponsor. The investigator and trial team must inform the R&D Department if an amendment to the protocol or the CTA is required and supply supporting information as appropriate as detailed in the amendment SOP for sponsored CTIMPs (see gSOP-09)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "5.8.2 An amendment is considered to be substantial when it is likely to have a significant impact on the:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Safety or physical or mental integrity of the subjects"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Scientific value of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Conduct or management of the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Quality or safety of any IMP used in the trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "5.8.3 Therefore substantial amendments may include, but are not limited to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "text": "5.8.4 Amendments to the trial protocol or Investigator's Brochure including: -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Changes to dose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Change of IMP supplier"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Eligibility criteria"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Statistical review or analysis (including sample size)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Amendments to change the Sponsor or Sponsor's name"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Urgent Safety Measures (USMs)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Temporary halt of a trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "\u25cf End of Trial (See section 5.8.8)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "5.8.5 It is the responsibility of the Sponsor to decide whether an amendment is deemed to be substantial. The R&D Department will review the proposed amendment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 1,
                "text": "Submission of a Substantial amendment to the MHRA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 1,
                "text": "5.8.6 Amendments to a CTA will be made in accordance with MHRA guidance. Detailed information on how to amend a CTA is available on the MHRA website"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 0,
                "text": "5.8.7 The CI/DI must liaise with the Clinical Trials Pharmacist regarding all amendments to the protocol of any MEHT sponsored CTIMPs and ensure the Pharmacy Clinical Trials Team are fully up to date and working to the most recent version of the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 0,
                "text": "5.8.8 For any pharmacy related amendments, the Pharmacist must review and approve the amendment, including any changes to the protocol and if resubmission to the MHRA is required, associated applications and regulatory documents."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "text": "5.8.9 The Pharmacist will send amendment approvals (if applicable) to the CI/DI and R&D Department (see gSOP-09)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 1,
                "text": "Submission of a Substantial Amendment to the REC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "text": "5.8.10 It is a requirement of the CTA that a favourable opinion of the REC is sought and maintained, if the amendment is considered substantial for ethical review. The CI/DI is responsible for the submission of all amendments to the REC (see gSOP-09)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "text": "Submission of a Substantial Amendment to R&D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 0,
                "text": "5.8.11 All amendments and required approvals will be submitted for approval to the R&D Department electronically. In multicentre trials it may be a requirement of the R&D approval at the participating sites to submit a copy of the amendment and relevant approvals. This will be co-ordinated by the CI/DI."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 1,
                "text": "Implementation of Substantial amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 0,
                "text": "5.8.12 The changes listed in a substantial amendment may NOT be implemented before receipt of the Notice of Acceptance of Amendment from the MHRA (if required), approval letter from the REC and local R&D confirmation; with the exception of USMs where the changes may be implemented immediately. Once all approvals are in place the R&D Department will notify the CI/DI and ensure that the correct documentation is in place to implement the amendment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 1,
                "text": "Non-Substantial amendments"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "text": "5.8.13 These are defined as a non-substantial administrative amendment that will have no significant implications for participants or for the conduct, management or scientific value of the study. Except for device studies, non-substantial amendments do not require MHRA or ethics approval. However, they  should still be submitted for notification."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 1,
                "text": "5.8.14 For further guidance please also refer to the HRA website. Temporary Halt of a Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "text": "5.8.15 If a MEHT sponsored CTIMP is halted temporarily, the Sponsor must be notified immediately by the CI/DI in writing. If a CTIMP is halted due to request from the Sponsor through the R&D or trial specific Oversight Committee, the MHRA and REC should be notified no later than 15 days from when the trial is temporarily halted."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 0,
                "text": "5.8.16 The notification must be made as a substantial amendment using the Notification of Amendment form detailing the reasons for the temporary halt."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "text": "5.8.17 It is the responsibility of the CI/DI to inform the participating Investigator sites of the temporary halt."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 1,
                "text": "5.8.18 If it is decided not to recommence a temporarily halted trial, the MHRA and REC must be notified within 15 days of this decision, using the End of Trial Declaration form."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 0,
                "text": "5.8.19 If an USM is implemented on trial for a serious breach of Good Clinical Practice (GCP) and/or the trial protocol is identified which requires expedited reporting to the MHRA and REC procedures detailed in the Sponsor's SOP on Serious Breaches should be followed (see gSOP-10)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 1,
                "text": "Development Safety Update Report (DSUR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 1,
                "text": "5.8.20 The R&D Department alongside the CI/DI and Clinical Trial Pharmacist (where required) will ensure that a DSUR is sent to the MHRA and REC no later than 60 days after the data lock date (see gSOP-15). A copy of the completed DSUR report will be retained in the TMF and a study specific Quality Assurance folder."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 1,
                "text": "End of a Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 0,
                "text": "5.8.21 The  end of  the  trial is  defined  as  the  last  patient,  last  visit,  unless  described differently in the trial protocol and original CTA application. The signed End of Trial form will be submitted within 90 days of the end of the trial to the MHRA and REC as detailed in the European Commission guidance (see gSOP-20)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 0,
                "text": "ICH GCP (1996), Section 1.8, 5.18 and 5.5.2"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "Research Governance Framework Second edition April 2005"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "text": "The Medicines for Human Use (Clinical Trials) Regulations 2004 SI 1031/200 1928/2006 (as amended from time to time)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "text": "EUCTD 2001/20/EC and GCP Directive 2005/28/EC"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "text": "Useful Web links for detailed guidance on procedures described in this SOP; Detailed guidance for the notification of a type A clinical trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "text": "Detailed guidance for the request for authorisation of a clinical trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "text": "MHRA WebPages for Submitting a CTA Application"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "text": "MHRA WebPages for Amendments to CTA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 0,
                "text": "MHRA WebPages for End of Trial Notifications"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "text": "The Medicines for Human Use (Clinical Trials) (2004) regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 2)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) - Any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 1,
                "text": "Adverse Reaction (AR) -  All untoward and unintended responses to an Investigational medicinal product related to any dose administered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) - The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects intended to discover or verify the clinical, pharmacological and / or other pharmacodynamic effects of one or more investigational medicinal product(s), and/or to identify any adverse reactions to one or more investigational medicinal product(s) and / or to study absorption, distribution, metabolism and excretion of one or more investigational medicinal product(s) with the object of ascertaining its (their) safety and / or efficacy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 1,
                "text": "Type A Clinical Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 0,
                "text": "A clinical trial but with no higher risk than standard medical care. The medicinal product must be licensed in an EU Member State and the trial relates to the licensed range of indications, dosage and form or, the trial involves off-label use (such as in paediatrics and in oncology), if this off-label use is established practice and supported by sufficient published evidence and/or guidelines"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 1,
                "text": "Type B Clinical Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 0,
                "text": "A  clinical  trial  but  with  somewhat  higher  risk  than  standard  medical  care and  involving medicinal products licensed in any EU Member State if such products are used for a new indication (different patient population/disease group), or substantial dosage modifications are made for the licensed indication or if they are used in combinations for which interactions are suspected. Also, trials involving medicinal products not licensed in any EU Member State if the active substance is part of a medicinal product licensed in the EU"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 1,
                "text": "Type C Clinical Trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 0,
                "text": "A clinical trial but with markedly higher risk than standard medical care and involving a medicinal product not licensed in any EU Member State A grading other than TYPE C may be justified if there is extensive class data or pre-clinical and clinical evidence."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial Authorisation (CTA) - Regulatory approval issued by a competent authority to conduct a clinical trial within an EU Member State."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 1,
                "prefix": 60.0,
                "text": "Data Lock Point - This should be the last day of the one year reporting period and the Development  Update Safety  Report  (DSUR)  should be  submitted  to the  Medicines and Healthcare Regulatory Authority (MHRA) and the Research Ethics Committee (REC) no later than  days after the data lock date."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 1,
                "text": "Development International Birth Date (DIBD) - The date that the Sponsor received the first Clinical Trial Authorisation (CTA) for that IMP. This date will determine the annual reporting period for the DSUR."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 1,
                "text": "Development Safety Update Report (DSUR) - A DSUR is an annual review and evaluation of pertinent safety information collected during the reporting period to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 0,
                "text": "\u25cf summarise the current understanding and management of identified and potential risks;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 0,
                "text": "\u25cf describe new safety issues that could have an impact on the protection of clinical trial subjects;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 0,
                "text": "\u25cf examine whether the information obtained by the sponsor during the reporting period is in accord with previous knowledge of the product's safety;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "text": "\u25cf provide an update on the status of the clinical investigation/development programme"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by a person of responsibility to carry out their task(s)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 1,
                "text": "Honorary Research Contract - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) - A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 231,
            "data": {
                "is_heading": 0,
                "text": "\u25cf used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 232,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 233,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 235,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 236,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 237,
            "data": {
                "is_heading": 1,
                "prefix": 2004.0,
                "text": "The Regulations - Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May  An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no 1928."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File - The Trial Master File (TMF) will be held at the principal site by the Sponsor, Chief Investigator or at the co-ordinating centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A TMF should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 239,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 240,
            "data": {
                "is_heading": 0,
                "text": "Research & Development Research Applications / MEHTSOP055/1.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 242,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Preliminary Equality Analysis"
            }
        },
        {
            "type": "image",
            "sequence_num": 243,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 244,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Research Applications / MEHTSOP055"
            }
        },
        {
            "type": "table",
            "sequence_num": 245,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 246,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 247,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 248,
            "data": {
                "url": "MEHTSOP055 Research Applications 1.0.001.png"
            }
        }
    ]
}